Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

print
PRINT
insite
SEARCH

Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

26-10-2018 | Renal cell carcinoma | ESMO 2018 | News

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

30-09-2019 | Renal cell carcinoma | Video | Article

Expert comment: RCC immunotherapy – biomarker round-up

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach

15-09-2017 | Renal cell carcinoma | ESMO 2017 | News

Nivolumab–ipilimumab duo ‘a new standard of care’ in first-line advanced RCC
Image Credits